沃森生物：披露云南证监局责令整改事项的具体整改情况

Core Viewpoint - Watson Bio announced that it received a decision from the Yunnan Securities Regulatory Bureau on December 18, 2025, regarding the non-compliance of its executive compensation decisions for 2023-2024, which were not submitted for review as required [1] Group 1 - The board of directors has taken the issue seriously and established a special team led by Chairman Li Yunchun to implement corrective measures [1] - Corrective actions include revising systems, improving decision-making procedures, organizing training, conducting self-examinations by independent directors, and holding relevant personnel accountable [1] - Most corrective measures are required to be completed before the annual shareholders' meeting in 2025, and the organization of training and accountability has already been completed, with the company issuing an apology regarding the issue [1]